Molbio Diagnostics GMP: Amazing 15% Listing Gain Signal, IPO Opens Today

Molbio Diagnostics GMP is drawing strong attention as the company’s IPO opened for subscription today, with early grey market activity hinting at a solid stock market debut. Here’s a complete breakdown of the GMP trend, IPO details, and company financials.

Molbio Diagnostics GMP Today

As of the latest reading, the Molbio Diagnostics GMP stands at around Rs. 125 per share. Based on the upper price band of Rs. 807, this points to an estimated listing price of roughly Rs. 932, translating into a potential listing gain of approximately 15.49%.

As always, GMP remains an unofficial, unregulated indicator and can shift quickly right up until the actual listing day.

About Molbio Diagnostics

Molbio Diagnostics is an innovative point-of-care (POC) diagnostics company that develops affordable, rapid, and accurate testing solutions for infectious and non-communicable diseases. Its flagship product, Truenat, is a portable, battery-powered PCR testing platform capable of delivering results within an hour, positioning the company as a notable player in India’s decentralized diagnostics space.

Molbio Diagnostics IPO: Key Details

• Price Band: Rs. 768 to Rs. 807 per share
• Lot Size: 18 shares (minimum investment of approximately Rs. 14,526 at the upper band)
• Issue Size: Approximately Rs. 939.70 crore
• Fresh Issue: Rs. 200 crore (24,80,246 shares)
• Offer for Sale: Rs. 739.70 crore (91,66,000 shares)
• Subscription Opens: August 10, 2026
• Allotment Date: August 13, 2026 (tentative)
• Listing Date: August 17, 2026 (tentative)
• Listing Exchanges: NSE and BSE
• Lead Manager: Kotak Mahindra Capital Co. Ltd.
• Registrar: Kfin Technologies Ltd.

Who Are the Promoters of Molbio Diagnostics?

The promoters of Molbio Diagnostics are Sriram Natarajan, Dr. Chandrasekhar Bhaskaran Nair, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram, and Exxora Trading LLP. Together, the promoter and promoter group hold an aggregate of 5,25,97,450 equity shares, amounting to 46.65% of the company’s pre-offer issued and paid-up equity share capital.

On the leadership side, Sangeetha Sriram serves as Chairman, while day-to-day operations are led by Indraneil Borkakoty as Managing Director, supported by Whole-Time Directors Sriram Natarajan, Dr. Chandrasekhar Nair, and Sangeetha Sriram herself.

Subscription Status

Subscription momentum picked up quickly. While the issue stood at 0.69 times subscribed in the early hours of day one, it climbed to 83% subscribed as the day progressed, reflecting steadily building investor interest as the window stayed open.o the bidding window.

Financial Snapshot (FY2026)

• Total Income: Rs. 1,455.17 crore, up 42% year-on-year
• Profit After Tax: Rs. 164.14 crore, up 18% year-on-year
• EBITDA: Rs. 328.24 crore

Unlike some recent new-age IPOs, Molbio Diagnostics enters the market as a profitable, growing business, which analysts often view as a stronger fundamental backdrop compared to loss-making listings.

Should You Subscribe?

The Molbio Diagnostics GMP suggests healthy listing-day sentiment, backed by genuine profitability and consistent revenue growth, both of which reduce (though don’t eliminate) listing-day risk compared to loss-making IPOs. As always, investors should weigh the company’s niche diagnostics focus and competitive landscape alongside the grey market signal before deciding.

Disclaimer: Grey Market Premium (GMP) figures are based on unofficial market trends and are not regulated by SEBI or any stock exchange. This article is for informational purposes only and should not be considered investment advice. Please consult a certified financial advisor before making any investment decisions.

For more IPO and market updates, check out our Business section, including our recent coverage of the Shiprocket IPO grey market premium.

Frequently Asked Questions

What is the Molbio Diagnostics GMP today?
The Molbio Diagnostics GMP stands at around Rs. 125 per share, suggesting an estimated listing price of roughly Rs. 932 against the Rs. 807 upper price band.

When does the Molbio Diagnostics IPO open?
The IPO opened for subscription on August 10, 2026.

Is Molbio Diagnostics profitable?
Yes. The company posted a Profit After Tax of Rs. 164.14 crore in FY2026, up 18% year-on-year, alongside 42% growth in total income.

What is the price band for the Molbio Diagnostics IPO?
The price band is set at Rs. 768 to Rs. 807 per share.

When will Molbio Diagnostics shares list?
Shares are expected to list on NSE and BSE on August 17, 2026, following a tentative allotment date of August 13, 2026.

What is the size of the Molbio IPO?
The Molbio Diagnostics IPO size is approximately Rs. 939.70 crore, comprising a Rs. 200 crore fresh issue and a Rs. 739.70 crore offer for sale.

Which IPO has the highest GMP today?
GMP rankings shift daily across the primary market, so there isn’t a single fixed answer. Molbio Diagnostics’ GMP of around Rs. 125, implying a roughly 15% listing gain, currently ranks among the stronger-performing IPOs in the market, though live GMP trackers should be checked for the most current comparison across all active issues.

Who are the promoters of Molbio Diagnostics?
The promoters are Sriram Natarajan, Dr. Chandrasekhar Bhaskaran Nair, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram, and Exxora Trading LLP, together holding 46.65% of the pre-offer equity.

What is the product of Molbio Diagnostics?
Its flagship product is Truenat, a portable, battery-powered PCR testing platform used for rapid point-of-care diagnosis of infectious and non-communicable diseases.